Cynda expects its net profit attributable to shareholders in the first half of the year to increase by 2443.43% year-on-year to 2834.73%, with the price of its main products rising
I'm LongbridgeAI, I can summarize articles.Cynda expects that the net profit attributable to the parent company in the first half of 2025 will increase by 2443.43% to 2834.73% year-on-year, with an estimated net profit of 130 million to 150 million yuan. After deducting non-recurring gains and losses, the net profit is expected to be 125 million to 145 million yuan. The price increase of the main product, oxazolone, has driven the growth of gross profit margin, while the market promotion of the new product, pyrazolyl quinazolone, has also contributed a new growth point to gross profit
According to the Zhitong Finance APP, Cynda (603086.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 130 million to 150 million yuan in the first half of 2025, an increase of 2443.43% to 2834.73% year-on-year. The company expects to achieve a net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, of 125 million to 145 million yuan in the first half of 2025.
During the reporting period, the market price of the company's main product, oxazolone, increased, driving the growth of the company's product gross profit margin; the company's newly developed product, pyrazole quinozole, was launched in the market this year and market promotion activities were carried out, contributing a new growth point to the company's gross profit